drugset

drugset / Trial / NCT00959439

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

NCT00959439 ↗

Phase 1 Completed 34 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).

Timeline

Start: 2002-03
Primary completion: 2002-05
Completion: 2002-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naproxen	Small molecule	375 mg	—

Indications